Plasma microRNA patterns linked to worse outcomes in coronary artery disease

Circulating microRNAs and Adverse Cardiovascular Outcomes in Patients With Coronary Artery Disease

This project will see if specific microRNAs in blood can help predict future heart attacks or other serious heart-related events in people with coronary artery disease.

Quick facts

• Study type: Observational
• Enrollment: 460 (estimated)
• Ages: 20 Years and up
• Sex: All
• Sponsor: National Taiwan University Hospital (other)
• Locations: 1 site (Taipei)
• Trial ID: NCT03635255 on ClinicalTrials.gov

What this trial studies

This observational project will search for circulating microRNA patterns in plasma that correlate with future adverse cardiovascular events and death among patients with established coronary artery disease. Investigators will use next-generation RNA sequencing (RNASeq) on plasma samples to identify candidate miRNAs, then validate top candidates in a larger independent cohort of CAD patients. Parallel laboratory experiments will test selected miRNAs in human aortic endothelial cells to explore possible mechanisms linking these miRNAs to endothelial dysfunction. The goal is to develop a plasma miRNA signature that could serve as a non-invasive prognostic tool for risk stratification in CAD.

Who should consider this trial

Good fit: Adults over 20 with a history of coronary artery disease or other cardiovascular disease (such as peripheral vascular disease) who can attend visits at National Taiwan University Hospital are the intended participants.

Not a fit: People without established CAD, or those with exclusion conditions such as significant valvular or congenital heart disease, active cancer, or on immunosuppressive therapy, are unlikely to benefit and participants should not expect direct therapeutic benefit from this observational project.

Why it matters

Potential benefit: If successful, a blood test measuring specific miRNAs could help doctors identify which CAD patients face higher risk of future adverse cardiovascular events and tailor preventive care.

How similar studies have performed: Several prior studies have reported promising links between circulating miRNAs and cardiovascular risk, but no widely adopted clinical miRNA test for CAD risk prediction has yet been established.

Eligibility criteria

Inclusion Criteria:

1. Male or female older than 20 years old.
2. Have a history of cardiovascular disease (including coronary heart disease, or peripheral vascular disease)

Exclusion Criteria:

Significant valvular or congenital heart disease, cancer, immunosuppressive therapy, or other conditions or treatment your physician thinks you have

Where this trial is running

Taipei

• NTUH — Taipei, Taiwan (RECRUITING)

Study contacts

• Principal investigator: Chau chung Wu, PhD — National Taiwan University Hospital
• Study coordinator: Chau chung Wu, PhD

Conditions: miRNA, CAD